Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Karanjin is a naturally occurring furanoflavonol, a type of benzofuran flavonoid, primarily isolated from the seeds of the karanja tree (Millettia pinnata, also called Pongamia glabra)[1][2][3][8][9]. It is used mainly as a bioinsecticide and acaricide in agriculture, but also studied for multiple biological activities, including antioxidant, anti-inflammatory, anti-ulcerogenic, antimicrobial, hypoglycemic, antidiabetic, and anticancer properties[1][2][4][5]. Pharmacological studies report its effects as a H+, K+-ATPase inhibitor (anti-ulcer activity), lipoxygenase inhibitor (anti-inflammatory activity), GLUT4 translocation stimulator (potential anti-diabetic action), and promoter of cancer cell apoptosis[1][2][4][5]. The compound is recognized in traditional Indian medicine, including Ayurveda and Siddha systems, for a range of ailments such as bronchitis, fever, arthritis, skin diseases, and gastrointestinal disorders, though it has not been developed as a pharmaceutical drug and does not have regulated medical indications[1][2][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on karanjin.